Related Experiment Video

Updated: Aug 29, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma

Masood A Shammas1, Robert J Shmookler Reis, Cheng Li

  • 1Boston VA Health Care System, Boston, Massachusetts, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 5, 2004
PubMed
Abstract

Insights

Telomestatin effectively inhibits telomerase activity and reduces telomere length in multiple myeloma cells, leading to cell death. This G-quadruplex drug shows promise for treating multiple myeloma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multiple myeloma is a cancer of plasma cells.
  • Telomerase is an enzyme crucial for maintaining telomere length, often upregulated in cancer cells.
  • Telomere length is critical for cell proliferation and survival.

Purpose of the Study:

  • To evaluate the efficacy of telomestatin, a G-quadruplex intercalating agent, as a therapeutic for multiple myeloma.
  • To investigate telomestatin's effects on telomerase activity and telomere length in myeloma cells.

Main Methods:

  • Myeloma cell lines (ARD, ARP, MM1S) were treated with telomestatin.
  • Telomerase activity, cell viability (trypan blue exclusion), telomere length, apoptosis, and gene expression were assessed.
  • Long-term treatment (3-5 weeks) at minimal effective concentrations was performed.

Main Results:

  • Telomestatin inhibited telomerase activity and reduced telomere length in all tested myeloma cell lines.
  • Apoptotic cell death was observed in treated myeloma cells.
  • Minimal changes in gene expression were noted, with no significant alterations in cell cycle, apoptosis, DNA repair, or recombination genes.

Conclusions:

  • Telomestatin demonstrates antiproliferative and proapoptotic effects in multiple myeloma cells by inhibiting telomerase and shortening telomeres.
  • Telomerase is a viable therapeutic target for multiple myeloma.
  • G-quadruplex agents targeting telomeric sequences warrant further investigation for multiple myeloma treatment.

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...